<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126528</url>
  </required_header>
  <id_info>
    <org_study_id>JHU-IRB2481</org_study_id>
    <secondary_id>02829-5</secondary_id>
    <nct_id>NCT01126528</nct_id>
  </id_info>
  <brief_title>Antenatal Vitamin D3 Supplementation in Bangladesh: Randomized Controlled Trial</brief_title>
  <acronym>AViDD-2</acronym>
  <official_title>The Effect of Antenatal Vitamin D Supplementation on Maternal-fetal Vitamin D Status and Neonatal Immune Function: a Randomized Controlled Trial in Bangladesh</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Centre for Diarrhoeal Disease Research, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized placebo-controlled trial of oral weekly vitamin D3&#xD;
      (cholecalciferol) supplementation during the third trimester of pregnancy among women in&#xD;
      Dhaka, Bangladesh. The overall goal of the study is to establish whether there is evidence&#xD;
      that improving vitamin D status among pregnant women in Bangladesh will enhance the&#xD;
      resistance of the infant offspring to infection.&#xD;
&#xD;
      The aims of the study are to assess the effect of supplementation on 1) maternal and infant&#xD;
      vitamin D status (based on blood concentrations of a vitamin D metabolite) and, 2) markers of&#xD;
      neonatal immune function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aims of this study are:&#xD;
&#xD;
      AIM #1 - To assess the effect of weekly antenatal administration of oral vitamin D3 (875&#xD;
      mcg/week = 35,000 IU week â‰ˆ 5,000 IU per day) started in the third trimester (26-29 weeks&#xD;
      gestation) on maternal vitamin D status and fetal-neonatal vitamin D status (cord blood), in&#xD;
      comparison to a placebo control supplement.&#xD;
&#xD;
      AIM #2 - To demonstrate the maternal and fetal safety of weekly maternal antenatal (second&#xD;
      and third-trimester) vitamin D supplementation at a dose of 875 mcg/week by monitoring&#xD;
      maternal serum calcium, urinary calcium excretion, cord blood calcium concentration, and&#xD;
      newborn clinical parameters.&#xD;
&#xD;
      AIM #3 - To measure the effect of antenatal vitamin D supplementation on selected biomarkers&#xD;
      of fetal-neonatal immune function in cord blood: in vitro stimulated cord blood mononuclear&#xD;
      cell (CBMC) LL-37 expression, gene expression related to inflammatory and immunoregulatory&#xD;
      pathways, Th1/Th2 cytokine secretion, and bactericidal properties.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum 25-hydroxyvitamin D concentration</measure>
    <time_frame>Maternal: during 3rd trimester; Neonatal (cord blood)</time_frame>
    <description>Biomarker of vitamin D status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum calcium concentration</measure>
    <time_frame>Maternal:3rd trimester; Cord blood.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Ca:Cr ration</measure>
    <time_frame>Maternal- 3rd trimester</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal immune function</measure>
    <time_frame>Cord blood</time_frame>
    <description>Selected markers of innate and adaptive immunity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant growth</measure>
    <time_frame>Postnatal observational follow-up phase</time_frame>
    <description>Infant growth parameters during postnatal follow-up, up to 12 months of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant and maternal postnatal vitamin D status</measure>
    <time_frame>Postnatal observational follow-up phase</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal serum calcium</measure>
    <time_frame>1st week postnatal</time_frame>
    <description>Infant serum calcium during the first week postnatal.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 (cholecalciferol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>35,000 IU per week, started at 26-29 weeks gestation, until delivery.</description>
    <arm_group_label>Vitamin D3</arm_group_label>
    <other_name>Cholecalciferol; Vigantol Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged 18 to &lt;35 years.&#xD;
&#xD;
          -  Current residence in Dhaka at a fixed address&#xD;
&#xD;
          -  Plans to have the delivery performed at the Shimantik maternity center, and to stay in&#xD;
             Dhaka throughout the pregnancy and for at least one month past the date of delivery.&#xD;
&#xD;
          -  Gestational age of 26th to 29th (inclusive), estimated based on the first day of the&#xD;
             last menstrual period (LMP).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any dietary supplement containing more than 400 IU/day (10 mcg/day) of vitamin&#xD;
             D within the month prior to enrolment, or refusal to stop taking supplemental vitamin&#xD;
             D at any dose after enrollment.&#xD;
&#xD;
          -  Current use of anti-convulsant or anti-mycobacterial (tuberculosis) medications.&#xD;
&#xD;
          -  Severe anemia (hemoglobin concentration &lt; 70 g/L).&#xD;
&#xD;
          -  Complicated medical or obstetric history that may increase the risk of preterm birth&#xD;
             or labor/delivery complications, based on self-report or clinical assessment by&#xD;
             physician (e.g., cardiovascular disease, uterine hemorrhage, placenta previa,&#xD;
             threatened abortion, hypertension, preeclampsia, preterm labor, or multiple&#xD;
             gestation).&#xD;
&#xD;
          -  Prior history of delivery of an infant with a major congenital anomaly, birth&#xD;
             asphyxia, or perinatal death (stillbirth or death within first week of life).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdullah Baqui, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>JHSPH; ICDDR,B</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rubhana Raqib, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Centre for Diarrhoeal Disease Research, Bangladesh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Centre for Diarrheal Disease Research, Bangladesh (ICDDR,B)</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>May 18, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>August 16, 2012</last_update_submitted>
  <last_update_submitted_qc>August 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins Bloomberg School of Public Health</investigator_affiliation>
    <investigator_full_name>Abdullah Baqui</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>Micronutrients</keyword>
  <keyword>Developing countries</keyword>
  <keyword>Bangladesh</keyword>
  <keyword>Infant, Newborn</keyword>
  <keyword>Reproductive Health</keyword>
  <keyword>Infant, Newborn, Diseases</keyword>
  <keyword>Perinatology</keyword>
  <keyword>Immunology</keyword>
  <keyword>cathelicidin</keyword>
  <keyword>Maternal Nutrition Physiology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

